Redeye ger en initial kommentar om den fullständiga Donanemab-datan samt förslaget från CMS om breda...
• Q2 report due on Friday, 11 August • Organic slowdown and FX headwinds on margins • Trading at 11x...
OrderYOYO announced on Tuesday, July 18th, the company’s performance during Q2-23.
Redeye retains its positive view of Avensia despite a softer Q2 than expected.
Redeye is encouraged to learn that Initiator Pharma has obtained positive data from its phase I drug...
Redeye leaves an initial comment following the Q2 report published by Magle this morning.
Redeye comments on Arise’s Q2 report, which came in better than expected.
• Net sales SEK 456m, -2% vs ABGSCe SEK 464m • EBITA SEK 58m, -4% vs ABGSCe SEK 60m • Share is +31% ...
Redeye provides an initial take on Enzymatica’s Q2 2023 report.
Carasent’s Q2 2023 report contained no big surprises.
Redeye states that adjusted EBITDA came in above Redeye's estimates but that sales was just below es...
Redeye returns with an update on Stille following its Q2 2023 report.
• Adj. EBITDA SEK -5m vs. ABGSCe SEK 1m • Cash of SEK 20m and an unused credit facility of SEK 20m •...
• Q2 report due on Thursday, 17 August • Solid performance in segments, OH costs still weigh • Needs...
Redeye expected higher sales in Q2, and so did Bong as well.
Redeye shortly comments on CLS’ announcement regarding its directed offset issue to underwriters.
Orderingången nådde nytt rekord.. Drivet av Westermo och delvis beroende på en engångsorder på 100 ...
Redeye is intrigued by today’s news that Saniona has entered into a collaboration agreement with the...
Tre nya avtal Rörelseresultat för kvartalet blev -13,1 mkr (-12,2) med intäkter om 5,8 mkr (7,2).
-8% organisk tillväxt men fortsatta förvärv.. Byggefterfrågan försämrades ytterligare under kvartale...
